Rationale for the use of angiotensin II receptor blockers in patients with left ventricular dysfunction (part I of II).
Almost 5 million individuals in the United States are diagnosed with chronic heart failure (HF), and the prevalence is increasing. Angiotensin-converting enzyme (ACE) inhibitors and beta blockers, neurohormonal antagonists that block the renin-angiotensin system (RAS) and the sympathetic nervous system, respectively, have been shown in clinical trials to reduce morbidity and mortality in patients with HF, and these therapies are now integral components of standard HF treatment. Yet, morbidity and mortality rates in HF remain unacceptably high, and the limitations of current standard therapies are becoming increasingly apparent. About 10% of patients with HF are unable to tolerate ACE inhibitors, often because of cough. In addition, ACE inhibition may not completely block the RAS because angiotensin II, the main end product of the RAS, can be generated via non-ACE enzymatic pathways. Angiotensin II receptor blockers (ARBs) may exert more complete RAS blockade than ACE inhibitors by interfering with the binding of angiotensin II at the receptor level, regardless of the enzymatic pathway of production. They are also better tolerated than ACE inhibitors and have been shown to improve symptoms and function in clinical trials in patients with HF. These factors provide a strong rationale for the study of the clinical effects of ARBs in patients with HF.
Levine
T Barry
TB
Division of Cardiology, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212-4772, USA. blevine@wpahs.org
Levine
Arlene B
AB
D000368:Aged; D057911:Angiotensin Receptor Antagonists; D005260:Female; D006801:Humans; D008297:Male; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000503:physiopathology
D057911:Angiotensin Receptor Antagonists